The site comprises of modern buildings where liquids/semi solids, cephalosporin, penicillin, hormone-containing products, inhaled products, sterile liquid ampoules and vials, and soft gel capsules are manufactured.
In the production site, a total of 126 million units were manufactured in 2016 compared to 128 million units in 2017.
Liquid / Semi Solid Manufacturing Unit
In the liquid and semi-solid area, syrup-drop and spray, creams and gels, suppository- and pessary-form products are manufactured using the state-of-art technology.
In the unit, in which a total of 24.1 million units were manufactured in 2016, a total of 21.3 million units were manufactured in 2017, 16 million of which are syrup, suspensions and drops, and 5.3 million are creams, gels and suppositories.
In the solids unit, tablets and film coated tablets, capsules and powder suspensions-form drugs are manufactured using the state-of-art technology.
In this part, in which 48.1 million units products were manufactured in 2016, a total of 45.3 million units of finished products, of which 43.4 million units were tablets/capsules, and 1.9 million units were suspensions, were packaged in 2017.
Cephalosporin Manufacturing Unit (Betalactam I)
Whereas, in the cephalosporin unit, 24.5 million units were manufactured in 2016, a total of 27 million units of pharmaceutical products were manufactured in 2017; 22.2 million units of injectable sterile powder vials, 1.8 million units of oral suspensions, and 3 million units of film-coated tablets and capsules.
An increase of 10.2% was achieved in total cephalosporin manufacture in 2017.
Penicillin Manufacturing Unit (Betalactam II)
Whereas, in the penicillin unit, 16.3 million units were manufactured in 2016, a total of 16.3 million units of pharmaceutical products were manufactured in 2017; 5,7 million units of injectable sterile powder vials, 4.2 million units of oral suspensions, and 6.4 million units of film-coated tablets.
Hormone Products Manufacturing Unit
Whereas, in the hormone products unit, 12 million units of products were manufactured in 2016; approximately 15,5 million units or product were manufactured in 2017; 2 million units of creams/pomades, 2 million units of tablets, and 11 million units of sterile ampoules, vials, and drops.
An increase of 29% was achieved in total hormone products manufacture in 2017.
Inhaled Products Manufacturing Unit
Approved by the Ministry of Health in 2014, the site has its own ventilation, water system and laboratory in a separate building. 1.35 million units of MDI and DPI were manufactured in 2016 compared with 2.2 million units in 2017, with an increase of approximately 63%.
Sterile Liquid Vial and Soft Gel Capsule Products Manufacturing Unit
In the Sterile Liquid Vial Unit, 3.65 million solvent vials and 643 thousand sterile liquid vials were manufactured in 2017. Product registration work in the soft gel capsule unit is underway.
Çerkezköy-1 Manufacturing successfully underwent inspections in 2017 by the Turkish Ministry of Health, and by Bulgarian, Iraqi and Kenyan healthcare authorities as well as customer inspections by the international companies of Abbott, Merck, Boehringer Ingelheim.